Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AA Phase 1b/2, Multicenter, Open-Label Study of DSP 7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab Pembrolizumab in Adult Subjects With Advanced Solid Tumors

Trial Profile

AA Phase 1b/2, Multicenter, Open-Label Study of DSP 7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab Pembrolizumab in Adult Subjects With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adegramotide/nelatimotide (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms WIZARD101CI
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 30 Jul 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Aug 2020.
    • 31 Aug 2018 Biomarkers information updated
    • 25 Apr 2018 According to a Boston Biomedical media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top